Anixa Biosciences Inc
ANIX
Company Profile
Business description
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Contact
3150 Almaden Expressway
Suite 250
San JoseCA95118
USAT: +1 408 708-9808
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 October 2025
Employees
5
Stocks News & Analysis
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
stocks
Why I dislike dividend stocks
If you need income then buying dividend stocks makes perfect sense. But if you don’t then it makes little sense because it’s likely to limit building real wealth. Here’s what you should do instead.
stocks
Chart of the Week: Ramsay Health Care margins to rebound
Charts from our latest stock pitch for Ramsay Health Care show a clear path to improved profitability.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,292.80 | 45.50 | -0.49% |
| CAC 40 | 8,188.59 | 111.59 | 1.38% |
| DAX 40 | 24,272.19 | 90.82 | 0.38% |
| Dow JONES (US) | 45,952.24 | 301.07 | -0.65% |
| FTSE 100 | 9,436.09 | 11.34 | 0.12% |
| HKSE | 25,473.09 | 415.42 | -1.60% |
| NASDAQ | 22,562.54 | 107.54 | -0.47% |
| Nikkei 225 | 47,640.98 | 636.76 | -1.32% |
| NZX 50 Index | 13,289.21 | 99.89 | -0.75% |
| S&P 500 | 6,629.07 | 41.99 | -0.63% |
| S&P/ASX 200 | 8,995.40 | 34.60 | -0.38% |
| SSE Composite Index | 3,877.20 | 39.03 | -1.00% |